Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis
Metabolic dysfunction–associated steatohepatitis (MASH) is a globally prevalent but intractable disease lacking effective pharmacotherapies. Here, we performed an integrated multilayered screening for pathogenic genes and druggable targets for MASH. We identified the subclass of metabolite-sensing G...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society for Clinical Investigation
2025-09-01
|
| Saila: | The Journal of Clinical Investigation |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1172/JCI173193 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
